Pfizer PFE Insider Ownership

Updated Oct 11, 2026

Over the past 12 months, Pfizer insiders bought $2.96 million of stock on the open market (114.86K shares) and sold $134,661 (5.28K shares).

• Pfizer's open-market purchases in the past 12 months came from 3 insiders, and its sales from one insider.
• Among Pfizer's insiders, the largest open-market purchases in the past 12 months were by Albert Bourla (Chairman & CEO), totaling $1 million (38K shares), most recently on August 12, 2026.
• On the sell side, Jennifer B. Damico (SVP & Controller) led open-market sales of Pfizer stock over the past 12 months with $134,661 (5.28K shares), most recently on August 5, 2026.
• Outside the open market, Pfizer insiders received 35.1K shares in stock awards, acquired 726.9K shares through option exercises and conversions and gave up 730.47K shares to cover taxes or exercise prices over the past 12 months.
• Per Business Quant data, Pfizer insiders hold 1.47Mn shares in total based on their latest Form 4 filings.
• By type of ownership, PFE insiders hold 99.05% of their shares directly (1.45Mn shares) and 0.95% indirectly (14K shares).
• Business Quant counts 15 insiders with holdings in Pfizer stock, among the officers, directors and 10% owners who have filed a Form 4 in the past two years.
• Pfizer's top three insider holders by shares held are Albert Bourla (Chairman & CEO, 429.17K shares), Sally Susman (Executive Vice President, 169.78K shares) and Douglas M. Lankler (Executive Vice President, 165.26K shares).
• Albert Bourla holds 29.25% of the combined insider position in Pfizer.
• Institutions accounted for 66.93% of PFE's outstanding shares in Q2 2026, insiders about 0.03% per their latest Form 4 filings, and other investors, including the public, about 33.04%.
• Over the past 12 months, 22 insiders reported transactions in Pfizer stock in 87 Form 4 filings.
• The insider holdings and trades above for Pfizer reflect Form 4 filings through October 1, 2026.